FibroGen Inc (NASDAQ:FGEN) — Market Cap & Net Worth
Market Cap & Net Worth: FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ:FGEN) has a market capitalization of $37.30 Million ($37.30 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23044 globally and #4969 in its home market, demonstrating a 5.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FibroGen Inc's stock price $9.22 by its total outstanding shares 4045445 (4.05 Million). Review FGEN total liabilities to assess the company's total debt and financial obligations.
FibroGen Inc Market Cap History: 2015 to 2026
FibroGen Inc's market capitalization history from 2015 to 2026. Data shows change from $123.26 Million to $37.30 Million (-9.45% CAGR).
Index Memberships
FibroGen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #659 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2192 of 3165 |
Weight: FibroGen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
FibroGen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FibroGen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
FibroGen Inc's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $123.26 Million | $180.83 Million | -$85.78 Million | 0.68x | N/A |
| 2016 | $86.57 Million | $179.58 Million | -$61.68 Million | 0.48x | N/A |
| 2017 | $191.75 Million | $125.67 Million | -$126.20 Million | 1.53x | N/A |
| 2018 | $187.22 Million | $212.96 Million | -$86.42 Million | 0.88x | N/A |
| 2019 | $173.51 Million | $256.58 Million | -$76.97 Million | 0.68x | N/A |
| 2020 | $150.05 Million | $176.32 Million | -$189.29 Million | 0.85x | N/A |
| 2021 | $57.04 Million | $235.31 Million | -$291.03 Million | 0.24x | N/A |
| 2022 | $64.81 Million | $140.73 Million | -$293.65 Million | 0.46x | N/A |
| 2023 | $3.59 Million | $46.80 Million | -$284.23 Million | 0.08x | N/A |
| 2024 | $2.14 Million | $29.62 Million | -$47.58 Million | 0.07x | N/A |
Competitor Companies of FGEN by Market Capitalization
Companies near FibroGen Inc in the global market cap rankings as of June 18, 2026.
Key companies related to FibroGen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
FibroGen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, FibroGen Inc's market cap moved from $123.26 Million to $ 37.30 Million, with a yearly change of -9.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.30 Million | +5.01% |
| 2025 | $35.52 Million | +1558.17% |
| 2024 | $2.14 Million | -40.26% |
| 2023 | $3.59 Million | -94.47% |
| 2022 | $64.81 Million | +13.62% |
| 2021 | $57.04 Million | -61.98% |
| 2020 | $150.05 Million | -13.52% |
| 2019 | $173.51 Million | -7.32% |
| 2018 | $187.22 Million | -2.36% |
| 2017 | $191.75 Million | +121.50% |
| 2016 | $86.57 Million | -29.77% |
| 2015 | $123.26 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of FibroGen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.30 Million USD |
| MoneyControl | $37.30 Million USD |
| MarketWatch | $37.30 Million USD |
| marketcap.company | $37.30 Million USD |
| Reuters | $37.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more